Christian Angermayer is a German entrepreneur, investor, and executive film producer, the founder of the private investment firm Apeiron Investment Group. Born in Germany in 1978, his career is defined by his intense focus on transformative technology and the 'Next Human Agenda'—promoting technologies that extend human healthspan and well-being.

His entrepreneurial journey began early: in 1998, while enrolled at the University of Bayreuth, he met professors working on RNA interference technology, leading him to co-found the biotech company Ribopharma AG at age 21. Ribopharma was later merged into Alnylam Pharmaceuticals, securing Angermayer's first major financial success and allowing him to drop out of college to pursue investment full-time. This provided the capital and conviction for his decades-long career as a lead investor in complex, high-stakes biotech and technology ventures.

Christian Angermayer's career is a series of successful, high-risk ventures across disparate, cutting-edge sectors, making him a major, and sometimes controversial, figure in global finance. After becoming a multimillionaire from the Ribopharma exit at age 25, he founded Apeiron Investment Group (his family office) to invest across Life Sciences, FinTech & Crypto, and Future Tech.

His most visible ventures are in the fields of longevity and mental health: he founded atai Life Sciences (NASDAQ: ATAI), a biotech company focused on developing psychedelics-based medicine (psilocybin, DMT) for mental health conditions, and co-founded longevity firms like Rejuveron and Cambrian Biopharma. He has also been an active investor in crypto (co-founding Plasma, a blockchain startup) and executive-produced 26 feature films. His commitment to the 'Enhanced Games'—a sporting event where performance enhancements are permitted—further underscores his philosophy of human enhancement and scientific progress.

Christian Angermayer's social impact is driven by his commitment to the Next Human Agenda—improving human healthspan and well-being through radical scientific progress. His investments in psychedelics-based medicine (atai) are framed as a direct effort to end the global mental health crisis.

He is a prominent thought leader on human enhancement and a sponsor of the XPRIZE Healthspan competition. His work with Blackrock Neurotech (BCI developer) provides new hope for people with neurological disorders, demonstrating a commitment to leveraging technology for large-scale medical solutions.

Christian Angermayer maintains the highly sophisticated, yet unconventional, style of a billionaire investor who deals in psychedelics and life extension. His attire is consistently high-quality, favoring European designer casual wear, often with a bold aesthetic. His public persona is defined by his controversial and confident advocacy for human enhancement.

Residing in Europe (Malta/London/Berlin), his luxury is the autonomy to fund massive, high-risk scientific research programs and maintain a vast global network of business and political contacts (including Peter Thiel). His life is dedicated to pushing the boundaries of science, finance, and human possibility.